“Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study”, J of Skin, vol. 9, no. 6, p. s603, Nov. 2025, doi: 10.25251/x2k3y515.